Table 2.

OR (95% CI) of achieving MDA at Month 12 according to the baseline variable values.

VariablesOR (95% CI), Univariate AnalysispOR (95% CI), Multivariate Analysisp
Male vs female2.67 (1.21–5.90)0.012.23 (0.58–8.575)NS
Age: ≤ 40 yrs vs > 40 yrs2.86 (0.75–10.8)NS0.946 (0.88–1.00)NS
Disease duration: ≤ 2 yrs vs > 2 yrs1.94 (0.48–7.86)NS1.03 (0.13–7.87)NS
Enthesitis: absence vs presence0.53 (0.22–1.24)NS0.61 (0.34–1.14)NS
Uveitis: absence vs presence1.19 (0.20–6.86)NS1.25 (0.35–6.99)NS
IBD: absence vs presence1.08 (0.54–1.56)NS1.07 (0.55–1.60)NS
Axial involvement absence vs presence4.26 (1.42–12.7)0.017.62 (1.38–41.9)< 0.01
HAQ, low vs high9.56 (2.11–43.24)< 0.0153.1 (3.25–869.6)< 0.01
ESR, high vs low3.32 (1.61–5.98)0.0311.9 (1.75–81.7)0.01
CRP, high vs low3 (1.07–8.38)0.0445.2 (3.64–560.6)< 0.01
PtGA, VAS ≤ 40 vs VAS > 402.77 (0.95–8.1)NS2.32 (0.87–6.51)NS
Pain, VAS ≤ 40 vs VAS > 402.77 (0.95–8.1)NS2.55 (0.66–9.31)NS
DMARD, concomitant use vs anti-TNF monotherapy0.39 (0.14–1.09)NS0.89 (0.77–1.23)NS
  • MDA: minimal disease activity; IBD: inflammatory bowel disease; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PtGA: patient’s global assessment: VAS: visual analog scale; DMARD: disease-modifying antirheumatic drugs; TNF: tumor necrosis factor; NS: not significant.